Qiu, H., & Guo, R. (2026 Supplement 19). Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial. Journal of Clinical Oncology, 44, 211-234.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Qiu, Haifeng, y Ruixia Guo. "Penpulimab Plus Anlotinib as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer: A Multicentre, Single-arm, Phase II Trial."
Journal of Clinical Oncology 44 (2026 Supplement 19): 211-234.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Qiu, Haifeng, y Ruixia Guo. "Penpulimab Plus Anlotinib as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer: A Multicentre, Single-arm, Phase II Trial."
Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 211-234.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.